Biological function of long noncoding RNAsnaRin HER2-positive breast cancer cells

Lee, Jeeyeon; Park, Ho Yong; Kim, Wan Wook; Lee, Soo Jung; Jeong, Jong Hwa; Kang, Sung Soo; Jung, Jin Hyang; Chae, Yee Soo

doi:10.1177/1010428317707374

Cited by 26 publications

(41 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relative to normal ones, the expression level of SNHG5 was elevated in 30 BRCA tissues and cell lines including MDA-MB-231, MCF7, SKBR3, T47D, BT474 and BT20. [25][26][27] Zahra et al also confirmed that SNHG5 was involved in cancer stage, overall grade, mitotic rate and tumor size in BRCA patients. 28 Notably, SNHG5 was detected to correlate with positive reaction of estrogen receptor, progesterone receptor and Her2/neu expression, 28 which were main subtypes of BRCA patients.…”

Section: Breast Cancer (Brca)mentioning

confidence: 99%

Latest Advances of Long Non-Coding RNA SNHG5 in Human Cancers

Han¹,

Shi²,

Cao³

et al. 2020

OTT

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have been potent regulators in the initiation and development of human cancers regarding their biological roles in the modulation of dosage compensation effect, epigenetics and cell differentiation. Recently, aberrant expression of lncRNA small nucleolar RNA host gene 5 (SNHG5) has been observed in various solid tumors, which was intently correlated with tumor range, metastasis, pathological stage and prognosis. Additional mechanical investigation disclosed that SNHG5 was involved in multiple cellular activities, including proliferation, migration, invasion, cell-cycle, apoptosis and autophagy, via targeting miRNAs, signaling pathways and other biological molecules or proteins. In this review, we summarized the latest advances made towards understanding the roles of SNHG5 in human cancers and further discussed potential methods that could be adopted for clinical interventions.

show abstract

Section: Breast Cancer (Brca)mentioning

confidence: 99%

Latest Advances of Long Non-Coding RNA SNHG5 in Human Cancers

Han¹,

Shi²,

Cao³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…The ZFAS1 gene is located on chromosome 20 (q13.13) and is transcribed from the antisense strand near the 5′-end of the protein-encoding gene Znfx1 and the hosts three C/D box snoRNAs (Snord12, -12b, and -12c) [10]. Various studies have identified ZFAS1 as a cancer oncogene in: glioma [11,12], gastric cancer [13,14,15,16,17], colorectal cancer [18,19,20,21], hepatocellular carcinoma [22], ovarian cancer [23,24], melanoma [25], non-small cell lung cancer [26], osteosarcoma [27], esophageal squamous cell carcinoma [28], and hematological malignancies [29,30]. However, suppressor roles for ZFAS1 lncRNA in breast cancer and hepatocellular carcinoma have also been reported [12,13,21].…”

Section: Introductionmentioning

confidence: 99%

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas

Kolenda

Guglas

Kopczyńska

et al. 2019

Cells

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease with high mortality. The identification of specific HNSCC biomarkers will increase treatment efficacy and limit the toxicity of current therapeutic strategies. Long non-coding RNAs (lncRNAs) are promising biomarkers. Accordingly, here we investigate the biological role of ZFAS1 and its potential as a biomarker in HNSCC. Methods: The expression level of ZFAS1 in HNSCC cell lines was analyzed using qRT-PCR. Based on the HNSCC TCGA data, the ZFAS1 expression profile, clinicopathological features, and expression of correlated genes were analyzed in patient tissue samples. The selected genes were classified according to their biological function using the PANTHER tool. The interaction between lncRNA:miRNA and miRNA:mRNA was tested using available online tools. All statistical analyses were accomplished using GraphPad Prism 5. Results: The expression of ZFAS1 was up-regulated in the metastatic FaDu cell line relative to the less aggressive SCC-25 and SCC-040 and dysplastic DOK cell lines. The TCGA data indicated an up-regulation of ZFAS1 in HNSCCs compared to normal tissue samples. The ZFAS1 levels typically differed depending on the cancer stage and T-stage. Patients with a lower expression of ZFAS1 presented a slightly longer disease-free survival and overall survival. The analysis of genes associated with ZFAS1, as well its targets, indicate that they are linked with crucial cellular processes. In the group of patients with low expression of ZFAS1, we detected the up-regulation of suppressors and down-regulation of genes associated with epithelial-to-mesenchymal transition (EMT) process, metastases, and cancer-initiating cells. Moreover, the negative correlation between ZFAS1 and its host gene, ZNFX1, was observed. The analysis of interactions indicated that ZFAS1 has a binding sequence for miR-150-5p. The expression of ZFAS1 and miR-150-5p is negatively correlated in HNSCC patients. miR-150-5p can regulate the 3′UTR of EIF4E mRNA. In the group of patients with high expression of ZFAS1 and low expression of miR-150-5p, we detected an up-regulation of EIF4E. Conclusions: In HNSCC, ZFAS1 displays oncogenic properties, regulates important processes associated with EMT, cancer-initiating cells, and metastases, and might affect patients’ clinical outcomes. ZFAS1 likely regulates the cell phenotype through miR-150-5p and its downstream targets. Following further validation, ZFAS1 might prove a new and valuable biomarker.

show abstract

“…The lncRNAs are involved in various biological processes, such as cell differentiation and cell cycle control, through transcription, post-transcription, and epigenetic regulation [21]. These RNAs play a role in tumorigenesis and a variety of human malignancies (e.g., papillary thyroid cancer, hepatocellular carcinoma, and breast neoplasms) [21]. The aberrant expression of Aurora kinases can disturb the cell cycle in mitosis and cytokinesis, thereby leading to genetic instability, followed by the stimulation of tumor development.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the knockdown of HOXA11-AS reportedly inhibits the formation of cell colonies and arrests the cell cycle at G0/G1 phase [22]. Lee et al showed that MER11C, PSF-inhibiting RNA, and SCA8 were also upregulated in the breast cancer cell lines (e.g., SK-BR3) [21].…”

Section: Discussionmentioning

confidence: 99%

Effect of CCT137690 on long non-coding RNA expression profiles in MCF-7 and MDA-MB-231 cell lines

Okcanoğlu¹,

Kayabaşı²,

Gündüz³

2019

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are involved in a range of biological processes, such as cellular differentiation, migration, apoptosis, invasion, proliferation, and transcriptional regulation. The aberrant expression of lncRNAs plays a significant role in several cancer types. Aurora kinases are increasingly expressed in various malignancies; accordingly, the inhibition of these enzymes may represent a novel approach for the treatment of various cancers. CCT137690, an Aurora kinase inhibitor, displays an anti-proliferative activity in human cancer cell lines. The aim of the present study was to investigate the anti-proliferative and cytotoxic effects of CCT137690 on estrogen receptor (ER)-positive human breast cancer cell line (MCF-7) and ER-negative human breast cancer cell line (MDA-MB-231). In addition, this study was targeted toward determining the changes induced in lncRNA expression levels following the initiation of Aurora kinase inhibitor treatment. The cytotoxic effects of CCT137690 were determined by means of the xCELLigence system. Furthermore, the anti-proliferative role of CCT137690 in breast cancer was investigated by checking the changes in lncRNA expression profiles using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The half-maximal inhibitory concentrations (IC50) of CCT137690 were determined as 4.5 μM (MCF-7) and 7.27 μM (MDA-MB-231). Several oncogenic lncRNAs (e.g., PRINS, HOXA1AS, and NCRMS) were downregulated in both ER-negative and ER-positive cell lines. On the other hand, tumor suppressor lncRNAs (e.g., DGCR5 and IGF2AS) were upregulated in the ER-positive cell line. After CCT137690 treatment, HOXA11AS and PCAT-14 lncRNAs were downregulated in the ER-positive cell lines. In addition, MER11C, SCA8, BC200, HOTAIR, PCAT-1, UCA1, SOX2OT, and HULC lncRNAs were downregulated in the ER-negative cell lines. The results of the present study indicated that Aurora kinase inhibitor CCT137690 could be a potential anti-cancer agent for breast cancer treatment.

show abstract

Biological function of long noncoding RNAsnaRin HER2-positive breast cancer cells

Cited by 26 publications

References 33 publications

<p>Latest Advances of Long Non-Coding RNA SNHG5 in Human Cancers</p>

<p>Latest Advances of Long Non-Coding RNA SNHG5 in Human Cancers</p>

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas

Effect of CCT137690 on long non-coding RNA expression profiles in MCF-7 and MDA-MB-231 cell lines

Contact Info

Product

Resources

About